Lack of differential sensitivity of normal hematopoietic stem cells and murine lymphoblastic leukemic cells to a lysosomotropic agent, N-dodecyl morpholine.
The effect of N-dodecyl morpholine (NDM), a lysosomotropic compound, on the clonogenic capacity of GK15, Sp2.0, Hb131, and L1210 lymphoblastic tumor cells and CFU-GM and CFU-S progenitor cells from DBA/2 mice was measured in order to evaluate the potential use of this compound for the purging of tumor-contaminated bone marrow (BM) in autologous BM transplantation. The growth of clonogenic tumor cells from all of the tested cell lines was inhibited with doses of NDM that also killed 100% CFU-GM and CFU-S, and no optimal dose could be found in this animal model to purge marrow while sparing sufficient stem cells to ensure engraftment in syngeneic BM transplantation.
D000818:Animals; D016026:Bone Marrow Transplantation; D002470:Cell Survival / Q000187:drug effects; D003114:Colony-Forming Units Assay; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D007945:Leukemia, Lymphoid / Q000473:pathology*; D008247:Lysosomes / Q000378:metabolism; D051379:Mice; D009025:Morpholines / Q000494:pharmacology*; D011828:Radiation Chimera; D014407:Tumor Cells, Cultured
D009025:Morpholines; C052796:N-dodecylmorpholine